Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics. - Wikidata - wikimedia - TriplyDB

Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics.

Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics.

http://www.wikidata.org/entity/Q44285833

about

The Production of a Stable Infliximab Powder: The Evaluation of Spray and Freeze-Drying for Production In Vivo Analysis of the Potency of Silicone Oil Microdroplets as Immunological Adjuvants in Protein Formulations Silicone Oil Microdroplets Can Induce Antibody Responses Against Recombinant Murine Growth Hormone in Mice.IgG Conformer's Binding to Amyloidogenic Aggregates.Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics Nebulization as a delivery method for mAbs in respiratory diseases.Physical Characterization and Innate Immunogenicity of Aggregated Intravenous Immunoglobulin (IGIV) in an In Vitro Cell-Based Model.Why the Immune System Should Be Concerned by Nanomaterials?Effect of growth hormone and IgG aggregates on dendritic cells activation and T-cells polarization.The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling.Comparison of NMR and Dynamic Light Scattering for Measuring Diffusion Coefficients of Formulated Insulin: Implications for Particle Size Distribution Measurements in Drug Products.Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti-TNF-α Antibodies after a Single Injection in Mice.Diffusion of Soluble Aggregates of THIOMABs and Bispecific Antibodies in Serum.Microparticles and Nanoparticles Delivered in Intravenous Saline and in an Intravenous Solution of a Therapeutic Antibody Product.Immunogenicity of protein aggregates of a monoclonal antibody generated by forced shaking stress with siliconized and nonsiliconized syringes in BALB/c mice.Inadequate storage of subcutaneous biological agents by patients with inflammatory bowel disease: Another factor driving loss of response?The Impact of Inadequate Temperature Storage Conditions on Aggregate and Particle Formation in Drugs Containing Tumor Necrosis Factor-Alpha Inhibitors.Modulating the immune system through nanotechnology.Flow microscopy imaging is sensitive to characteristics of subvisible particles in peginesatide formulations associated with severe adverse reactions.Biosimilarity under stress: A forced degradation study of Remicade® and Remsima™.

P2860

Q28554493-5E27D709-8DFE-4831-99DC-601A004E6773 Q30376902-5C87253E-4B2B-4EE0-BE74-1A43C44D9B9A Q30386156-43AF4A84-305C-4E33-A65A-5A35DCFE0C70 Q35772596-3F2E965F-53D9-434B-B68A-A050BB10399E Q35856534-5F7D5BF4-B690-44C0-98E7-AD0F8CAD5608 Q36095866-70D41969-75C6-4012-BF76-6E9490407D95 Q38306677-4D222047-2AC4-4AFD-8302-8893E9A66A2D Q38781432-E5E93C20-4EEB-4A47-BABF-64333F70A009 Q39336982-D0A60F85-78C0-4164-894D-E535FEE06A2E Q40514614-F0970061-CC8C-4FFB-9B2C-AB3B76902968 Q41953123-AEFEE280-B18C-498D-A7BF-35AAE2EC4A25 Q46323700-0A66335E-9154-4126-8163-58EB8A5A926E Q46355891-BA74449A-7053-4A19-85F5-56F64CCD83F0 Q47144575-5CDE42F5-2A29-44E1-A721-D36D18140B84 Q48036411-7F98B6A3-9C4E-40BD-A9F7-394DD826C1A6 Q48238341-A624A302-4361-430C-BE5F-AC425C908A83 Q48336044-7A7B5B06-EA84-4538-B1F0-1BA5BD7A296A Q48502841-DEDB69E4-D39A-499E-AE78-1A9A1575AE91 Q48630939-F2070596-295E-4798-A92C-346EA2AAE35C Q50153560-1FA062E9-6327-493C-B957-F86B7CE069BC Q50508037-62552669-F1CF-40DB-B22A-E670F4465204

P2860

Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics.

http://www.wikidata.org/entity/Q44285833

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Small amounts of sub-visible a ...... oclonal antibody therapeutics.

@en

Small amounts of sub-visible a ...... oclonal antibody therapeutics.

@nl

type

label

Small amounts of sub-visible a ...... oclonal antibody therapeutics.

@en

Small amounts of sub-visible a ...... oclonal antibody therapeutics.

@nl

prefLabel

Small amounts of sub-visible a ...... oclonal antibody therapeutics.

@en

Small amounts of sub-visible a ...... oclonal antibody therapeutics.

@nl

P1433

Q44285833-9506DE65-53A0-4D0D-8055-996D3AAF5D1C

P1476

Q44285833-E46B9CAF-4BAF-4B22-9639-320EE96957CE

P2093

Q44285833-3886BDBF-E7C7-48AF-812A-7FA7132D62F6

Q44285833-5FBDC001-C74D-459D-95A3-3B8DED48D156

Q44285833-64C413BF-A276-4852-A395-17AE1B555938

Q44285833-6F4E9969-9474-4CC6-BA18-DB4D2F24536F

Q44285833-91A24A11-C44D-49F3-B823-5D4EDE4DF114

Q44285833-985A2B76-3DBC-41D7-8C09-6F06015007AD

Q44285833-B176B3DF-4620-4E4C-B1B5-BF90A8FB738E

Q44285833-C0F67ABC-688D-4C2A-BC1B-5EF272A2D61F

Q44285833-F9A0B6FE-E1FE-4CB6-A42E-F28B6ABB4EA4

Q44285833-FBB87A12-A9DC-421D-BBB2-8C8F90C7A989

P2860

Q44285833-00E4D64C-73BF-40DA-84E0-880DC434C6A0

Q44285833-02083CBB-6E44-4458-A8D9-7C89B3285FF2

Q44285833-1304A2D7-1DD1-41C0-B41D-7084C9A652B0

Q44285833-1BC3A80F-AD6F-4362-9612-01849E4762C4

Q44285833-1C89F58A-DE9A-4EBB-883A-202825C8958F

Q44285833-1E5D8DC0-CE2C-4BEB-824E-F1D2526225ED

Q44285833-40CB323E-1ADE-426A-AF68-0BA1C3D1D473

Q44285833-4F18FC2E-4F89-4781-AFDE-AC0E91F7BB85

Q44285833-5634307B-C1CC-4EA7-B853-7375491CE687

Q44285833-56D7C395-E0CB-46AE-B20D-2A4C034ACDBA

P304

Q44285833-71333962-F114-4212-A45E-7158D5BF90D8

P31

Q44285833-A594EF19-F1E2-491E-B0D9-F9A11C170355

P356

Q44285833-8DAE9D65-1F1B-4BC3-9C70-3D3F07C4A2BC

P433

Q44285833-6EEB56FF-A5E5-45F5-84EC-5AE6FE0D4F98

P478

Q44285833-92560208-7F63-43DE-A9E4-512B4EE3F273

P577

Q44285833-B5B07ACB-AE71-40BA-8B62-C6A7C2620D4D

P698

Q44285833-EA937761-0A47-4A3A-B889-6A69A4AE94A6

P921

Q44285833-575A037E-F763-4865-9C80-3F3A0EFAEDF0

P356

S11095-014-1541-X

P1433

Pharmaceutical Research

P1476

Small amounts of sub-visible a ...... oclonal antibody therapeutics.

@en

P2093

Andrea Hawe

http://www.w3.org/2001/XMLSchema#string

Christine J Bryson

http://www.w3.org/2001/XMLSchema#string

Edward A Cloake

http://www.w3.org/2001/XMLSchema#string

Katie Welch

http://www.w3.org/2001/XMLSchema#string

Mark H Fogg

http://www.w3.org/2001/XMLSchema#string

Maryam Ahmadi

http://www.w3.org/2001/XMLSchema#string

Matthew P Baker

http://www.w3.org/2001/XMLSchema#string

Stefan Romeijn

http://www.w3.org/2001/XMLSchema#string

Vasco Filipe

http://www.w3.org/2001/XMLSchema#string

Wim Jiskoot

http://www.w3.org/2001/XMLSchema#string

P2860

A critical role for IL-21 in regulating immunoglobulin production

Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro

Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b.

Response of a concentrated monoclonal antibody formulation to high shear

Fluorescence single particle tracking for the characterization of submicron protein aggregates in biological fluids and complex formulations.

Classification and characterization of therapeutic antibody aggregates.

IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism.

Lymphatic transport of proteins after subcutaneous administration.

Detection and characterization of subvisible aggregates of monoclonal IgG in serum

Inhibition of aberrant circulating Tfh cell proportions by corticosteroids in patients with systemic lupus erythematosus.

P304

1383-1394

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11095-014-1541-X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25319104

http://www.w3.org/2001/XMLSchema#string

P921